Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
Details
Serval ID
serval:BIB_78DF1673CACD
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
Journal
Acta Oncologica (stockholm, Sweden)
ISSN
1651-226X (Electronic)
ISSN-L
0284-186X
Publication state
Published
Issued date
2011
Peer-reviewed
Oui
Volume
50
Number
5
Pages
630-635
Language
english
Notes
Publication types: Evaluation Studies ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
BACKGROUND: Patients with recurrent high-grade glioma (HGG) have a poor prognosis and there is no defined standard of care. High levels of vascular endothelial growth factor (VEGF) expressed in HGG make the anti-VEGF monoclonal antibody bevacizumab (BEV) of particular interest.
PATIENTS AND METHODS: In an ongoing registry data were collected from patients who have received BEV for the treatment of recurrent HGG. The primary objective was the identification of any clinical benefit as assessed by change in Karnofsky Performance Score (KPS), decreased steroid use and duration of treatment.
RESULTS: Two hundred and twenty-five patients with HGG were included (176 glioblastoma; 49 anaplastic glioma; median age 52 years). KPS improved in 10% of patients and remained stable in 68%. Steroids were stopped in 37.6% of patients. Median duration of treatment was 5.5 months; 19.1% of patients were treated for more than 12 months. Median overall survival from beginning of BEV treatment was 8.5 months. At the time of analysis, 169 patients (75.1%) had died and 56 patients (24.9%) were alive. Only 21 patients (9.3%) discontinued treatment due to toxicity.
CONCLUSIONS: Our data reveal valuable palliation with preservation of KPS and an option for steroid withdrawal in patients treated with BEV, supporting the role of this therapy in late-stage disease.
PATIENTS AND METHODS: In an ongoing registry data were collected from patients who have received BEV for the treatment of recurrent HGG. The primary objective was the identification of any clinical benefit as assessed by change in Karnofsky Performance Score (KPS), decreased steroid use and duration of treatment.
RESULTS: Two hundred and twenty-five patients with HGG were included (176 glioblastoma; 49 anaplastic glioma; median age 52 years). KPS improved in 10% of patients and remained stable in 68%. Steroids were stopped in 37.6% of patients. Median duration of treatment was 5.5 months; 19.1% of patients were treated for more than 12 months. Median overall survival from beginning of BEV treatment was 8.5 months. At the time of analysis, 169 patients (75.1%) had died and 56 patients (24.9%) were alive. Only 21 patients (9.3%) discontinued treatment due to toxicity.
CONCLUSIONS: Our data reveal valuable palliation with preservation of KPS and an option for steroid withdrawal in patients treated with BEV, supporting the role of this therapy in late-stage disease.
Keywords
Adult, Aged, Angiogenesis Inhibitors/therapeutic use, Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized, Brain Neoplasms/diagnosis, Brain Neoplasms/drug therapy, Clinical Trials as Topic, Female, Glioma/diagnosis, Glioma/drug therapy, Humans, Male, Middle Aged, Prognosis, Recurrence, Registries, Standard of Care, Treatment Outcome, Young Adult
Pubmed
Create date
19/02/2014 22:26
Last modification date
20/08/2019 15:35
Usage data
